We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · December 28, 2021

Neoadjuvant Talimogene Laherparepvec Plus Surgery for Resectable Stage IIIB–IVM1a Melanoma

Nature Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
Nat. Med. 2021 Oct 01;27(10)1789-1796, R Dummer, DE Gyorki, J Hyngstrom, AC Berger, R Conry, L Demidov, A Sharma, SA Treichel, H Radcliffe, KS Gorski, A Anderson, E Chan, M Faries, MI Ross

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading